It does not prescribe or dispense medications itself, but facilitates access through a verified provider and pharmacy network
Ready to explore whether GLP-1 medications could help you
Unlike Ribupatide, Orforglipron is: a small molecule drug not a peptide specifically designed for oral bioavailability This distinction may affect: manufacturing scalability stability storage requirements dosing flexibility Ribupatide, however, may potentially benefit from peptide-based receptor activity that more closely resembles injectable incretin therapies
GLP-1-B12 injections may be a great solution
Flags theoretical pathologic angiogenesis potential: PMC12446177 Evidence summary Preclinical: IBD/colitis models: High remission rates, restored mucosal architecture, improved barrier function Tendon repair: Accelerated healing, improved tensile strength, reduced fibrosis Neurovascular: Sciatic nerve protection, enhanced blood vessel growth in nerve tissue Human data (emerging): Interstitial cystitis pilot (2024, n=12): 10/12 complete resolution, 2/12 at 80% improvement IV safety study (2025, n=2): no adverse effects on cardiac, hepatic, renal, or glucose biomarkers Knee series (Lee): 17 patients identified, 16 analysed
A wearable alternative to pills or injections, designed for targeted recovery support